Literature DB >> 754380

The diagnosis and treatment of sickled erythrocytes in human hyphemas.

M F Goldberg.   

Abstract

Four patients with sickle cell hemoglobinopathies (one SC; three AS) and hyphemas were found to have more erythrocytes sickled in their anterior chambers than in their circulating venous blood. Intraocular pressure was severely elevated, despite relatively small amounts of intracameral blood. Systemic hypotensive agents were not always successful in reducing IOP, and in patients with sickle cell hemoglobinopathy, are probably contraindicated in high or repeated dose regimens. Moderate elevation of IOP in sickle cell hemoglobinopathy patients may produce rapid deterioration of visual function, perhaps because of a greater effect on vascular perfusion in the CRA and optic nerve. Early anterior chamber paracentesis may be the best treatment for this type of hyphema-induced secondary glaucoma.

Entities:  

Mesh:

Year:  1978        PMID: 754380      PMCID: PMC1311633     

Source DB:  PubMed          Journal:  Trans Am Ophthalmol Soc        ISSN: 0065-9533


  35 in total

1.  HEMOLYTIC GLAUCOMA. AN UNUSUAL CAUSE OF ACUTE OPEN-ANGLE SECONDARY GLAUCOMA.

Authors:  R H FENTON; L E ZIMMERMAN
Journal:  Arch Ophthalmol       Date:  1963-08

2.  UNILATERAL GLAUCOMA ASSOCIATED WITH SICKLE-CELL RETINOPATHY.

Authors:  M BONIUK; G L BURTON
Journal:  Trans Am Acad Ophthalmol Otolaryngol       Date:  1964 Mar-Apr

3.  RHEOLOGY OF PACKED RED BLOOD CELLS CONTAINING HEMOGLOBINS A-A, S-A, AND S-S.

Authors:  L DINTENFASS
Journal:  J Lab Clin Med       Date:  1964-10

4.  Sequential electron micrography of sickling.

Authors:  J W REBUCK; R M STURROCK; R W MONTO
Journal:  Lab Invest       Date:  1955 May-Jun       Impact factor: 5.662

5.  Red cell filtration and the pathogenesis of certain hemolytic anemias.

Authors:  J H JANDL; R L SIMMONS; W B CASTLE
Journal:  Blood       Date:  1961-08       Impact factor: 22.113

6.  Permanent sickle cell preparations.

Authors:  P STENTON
Journal:  J Clin Pathol       Date:  1959-09       Impact factor: 3.411

7.  Lesions in kidneys removed for unilateral hematuria in sickle-cell disease.

Authors:  F K MOSTOFI; C F VORDER BRUEGGE; L W DIGGS
Journal:  AMA Arch Pathol       Date:  1957-04

8.  Studies on the destruction of red blood cells. X. The biophysics and biology of sickle-cell disease.

Authors:  J W HARRIS; H H BREWSTER; T H HAM; W B CASTLE
Journal:  AMA Arch Intern Med       Date:  1956-02

9.  Filtration characteristics of sickle cells: rates of alteration of filterability after deoxygenation and reoxygenation, and correlations with sickling and unsickling.

Authors:  M J Messer; J W Harris
Journal:  J Lab Clin Med       Date:  1970-10

10.  Low-dose methazolamide and intraocular pressure.

Authors:  R A Stone; T J Zimmerman; D H Shin; B Becker; M A Kass
Journal:  Am J Ophthalmol       Date:  1977-05       Impact factor: 5.258

View more
  4 in total

1.  Vitreoretinal management and surgical outcomes in proliferative sickle retinopathy: a case series.

Authors:  Royce W S Chen; Harry W Flynn; Wen-Hsiang Lee; D Wilkin Parke; Ryan F Isom; Janet L Davis; William E Smiddy
Journal:  Am J Ophthalmol       Date:  2013-12-31       Impact factor: 5.258

Review 2.  Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management.

Authors:  Samir K Ballas; Muge R Kesen; Morton F Goldberg; Gerard A Lutty; Carlton Dampier; Ifeyinwa Osunkwo; Winfred C Wang; Carolyn Hoppe; Ward Hagar; Deepika S Darbari; Punam Malik
Journal:  ScientificWorldJournal       Date:  2012-08-01

3.  The injection of air/oxygen bubble into the anterior chamber of rabbits as a treatment for hyphema in patients with sickle cell disease.

Authors:  Emre Ayintap; Uğurcan Keskin; Fariz Sadigov; Mesut Coskun; Nilufer Ilhan; Sedat Motor; Hilal Semiz; Nihan Parlakfikirer
Journal:  J Ophthalmol       Date:  2014-04-07       Impact factor: 1.909

Review 4.  [Maculopathy in sickle cell disease].

Authors:  Isabel Bachmeier; Christiane Blecha; Jürgen Föll; Daniel Wolff; Herbert Jägle
Journal:  Ophthalmologe       Date:  2021-01-27       Impact factor: 1.059

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.